Safety and Efficacy of Rifampicine 600 mg, Moxifloxacine 400mg and Minocycline 100 mg for leprosy patients: An open ended randomized trial
Phase 3
- Conditions
- Health Condition 1: A309- Leprosy, unspecified
- Registration Number
- CTRI/2019/02/017812
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
New untreated leprosy case
Exclusion Criteria
Any patient condition (Pregnancy, Lactation, Co-infection TB,Diebetes, Hypertension, Peripheral Vascular Diseases, Choronic Artery Diseses) that would be expected to confound with patients monitoring would not be included in the study. Patients who present with reaction or disability needing steroid would also not be included
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cure of patients, <br/ ><br>Relapses, developement of disability if any, DefaultTimepoint: 6 months <br/ ><br>12 months <br/ ><br>24 months <br/ ><br>
- Secondary Outcome Measures
Name Time Method Reactions and side effectsTimepoint: 12 months <br/ ><br>24 months <br/ ><br>36 months